Ultragenyx Pharmaceutical...

AI Score

0

Unlock

40.11
-3.05 (-7.07%)
At close: Jan 14, 2025, 3:59 PM
39.10
-2.52%
Pre-market Jan 15, 2025, 04:18 AM EST
undefined%
Bid 38.12
Market Cap 3.70B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -6.35
PE Ratio (ttm) -6.32
Forward PE n/a
Analyst Buy
Ask 46.12
Volume 788,455
Avg. Volume (20D) 842,022
Open 44.52
Previous Close 43.16
Day's Range 39.79 - 44.52
52-Week Range 37.02 - 60.37
Beta undefined

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2014
Employees 1,276
Stock Exchange NASDAQ
Ticker Symbol RARE

Analyst Forecast

According to 14 analyst ratings, the average rating for RARE stock is "Buy." The 12-month stock price forecast is $84.5, which is an increase of 110.67% from the latest price.

Buy 92.86%
Hold 7.14%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Ultragenyx Pharmaceutical Inc. is scheduled to release its earnings on Feb 13, 2025, during market hours.
Analysts project revenue of $144.99M, reflecting a 13.81% YoY growth and earnings per share of -1.35, making a -11.18% decrease YoY.
5 months ago · Source
+14.31%
Ultragenyx Pharmaceuticals shares are trading high... Unlock content with Pro Subscription
5 months ago · Source
-1.93%
Ultragenyx Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates.